Just a month after taking up the CEO role at Legend Biotech, Frank Zhang has been forced to step aside by the board following an investigation into suspected illegal activity by Chinese customs.

Legend Biotech Corporation Sponsored ADR (LEGN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most ...

Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The firm had revenue of $186.50 million for the quarter, compared to analysts’ expectations of $179. ...

SOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ...

Frank Zhang never meant to become a photographer. In fact, the award-winning image-maker, whose work has graced the pages of Harper’s Bazaar, L’Officiel, and so on, featured in Forbes ...

SOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET ...

Legend Biotech Corporation Sponsored ADR (LEGN) shares rallied 5.1% in the last trading session to close at $33.74. This move can be attributable to notable volume with a higher number of shares ...

Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The firm’s quarterly revenue was up 134.6% compared to the same quarter last year.

RBC Capital analyst Leonid Timashev reiterated a Buy rating on Legend Biotech (LEGN – Research Report) today and set a price target of $84.00. The company’s shares closed yesterday at $32.24.

Legend Biotech Corporation Sponsored ADR (LEGN) shares rallied 5.1% in the last trading session to close at $33.74. This move can be attributable to notable volume with a higher number of shares being ...